Cancer: Prescription Drugs

Department of Health and Social Care written question – answered at on 8 April 2024.

Alert me about debates like this

Photo of Baroness Ritchie of Downpatrick Baroness Ritchie of Downpatrick Non-affiliated

To ask His Majesty's Government what assessment they have made of the impact of the National Institute for Health and Care Excellence’s severity modifier on the prescribing of cancer medicines.

Photo of Lord Markham Lord Markham The Parliamentary Under-Secretary for Health and Social Care

The National Institute for Health and Care Excellence (NICE) published its updated manual for health technology evaluations in January 2022, and has introduced a number of changes to make its methods and processes fairer, faster, and more consistent.

This includes the introduction of a broader severity modifier in place of the end-of-life modifier. NICE has been monitoring the impact of the changes that it introduced and analysis carried out by NICE for the first year of the updated manual’s implementation shows that NICE’s committee accepted 11 out of 13 cases where the company applied for a severity modifier, with eight of these being for cancer medicines.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.